Einzeltreffer — DigiBib

Clinical reports show that the management of cancer patients infected with SARS-CoV-2 requires modifications. Understanding of cancer-relevant mechanisms engaged by the virus is essential for the evidence-based management of cancer. The network of SARS-CoV-2 regulatory mechanisms was used to study potential engagement of oncogenes, tumor suppressors, other regulators of tumorigenesis and clinical markers used in the management of cancer patients. Our network analysis confirms links between COVID-19 and tumorigenesis that were predicted in epidemiological reports. The COVID-19 network shows the involvement of tumorigenesis regulators and clinical markers. Regulators of cell proliferation, death, migration, and the immune system were retrieved. Examples are pathways initiated by EGF, VEGF, TGFβ and FGF. The SARS-CoV-2 network engages markers for diagnosis, prognosis and selection of treatment. Intersection with cancer diagnostic signatures supports a potential impact of the virus on tumorigenesis. Clinical observations show the diversity of symptoms correlating with biological processes and types of cells engaged by the virus, e.g. epithelial, endothelial, smooth muscle, glial and immune system cells. Our results describe an extensive engagement of cancer-relevant mechanisms and clinical markers by COVID-19. Engagement by the virus of clinical markers provides a rationale for clinical decisions based on these markers.

Titel:	COVID-19 engages clinical markers for the management of cancer and cancer-relevant regulators of cell proliferation, death, migration, and immune response.
Autor/in / Beteiligte Person:	Souchelnytskyi, S ; Nera, A ; Souchelnytskyi, N
Link:	Full Text Finder (Volltext)
Zeitschrift:	Scientific reports, Jg. 11 (2021-03-04), Heft 1, S. 5228
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2021
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-021-84780-y
Schlagwort:	Carcinogenesis Humans Neoplasms complications Biomarkers, Tumor metabolism COVID-19 metabolism Neoplasms metabolism SARS-CoV-2 metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Sci Rep] 2021 Mar 04; Vol. 11 (1), pp. 5228. <i>Date of Electronic Publication: </i>2021 Mar 04. MeSH Terms: Biomarkers, Tumor / metabolism ; COVID-19 / metabolism ; Neoplasms / metabolism ; SARS-CoV-2 / metabolism ; Carcinogenesis ; Humans ; Neoplasms / complications References: Lancet Oncol. 2020 May;21(5):628. (PMID: 32213339) ; Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026) ; JAMA Oncol. 2020 May 1;6(5):631-632. (PMID: 32236504) ; Science. 2020 May 1;368(6490):473-474. (PMID: 32303591) ; ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. (PMID: 32167747) ; Tumour Biol. 2015 Jul;36(7):5171-7. (PMID: 25663464) ; Dermatol Ther. 2020 Sep;33(5):e13430. (PMID: 32314460) ; Oncologist. 2020 Jun;25(6):e936-e945. (PMID: 32243668) ; J Exp Clin Cancer Res. 2019 Apr 25;38(1):173. (PMID: 31023337) ; Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151) ; Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145) ; Wiley Interdiscip Rev Syst Biol Med. 2020 Nov;12(6):e1489. (PMID: 32307915) ; Virus Res. 2016 Jun 15;218:2-9. (PMID: 26795869) ; J Infect. 2020 Aug;81(2):318-356. (PMID: 32298677) ; Emerg Microbes Infect. 2020 Dec;9(1):221-236. (PMID: 31987001) ; Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) ; Clin Infect Dis. 2020 Nov 19;71(16):2052-2060. (PMID: 32307550) ; Food Chem Toxicol. 2020 Dec;146:111769. (PMID: 32979398) ; Cancer Lett. 2016 Jul 1;376(2):268-77. (PMID: 27063099) ; Emerg Microbes Infect. 2020 Dec;9(1):1748-1760. (PMID: 32691695) ; Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. (PMID: 32329877) ; Sci Data. 2020 May 5;7(1):136. (PMID: 32371892) ; Mol Cell Proteomics. 2012 Jul;11(7):M111.014738. (PMID: 22371486) ; J Virol. 2020 Mar 17;94(7):. (PMID: 31996437) ; Cell. 2009 Dec 24;139(7):1255-67. (PMID: 20064372) ; Ann Intern Med. 2020 Aug 18;173(4):268-277. (PMID: 32374815) ; J Clin Virol. 2020 Jul;128:104386. (PMID: 32388469) ; BMJ. 2020 Mar 25;368:m1174. (PMID: 32213482) ; Oncol Rep. 2010 Apr;23(4):941-8. (PMID: 20204277) ; Cell. 2020 Aug 6;182(3):685-712.e19. (PMID: 32645325) ; Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658) ; Nat Rev Microbiol. 2019 Jan;17(2):110-123. (PMID: 30514982) ; BMC Anesthesiol. 2020 Jul 20;20(1):177. (PMID: 32689937) ; PLoS One. 2017 Aug 15;12(8):e0181711. (PMID: 28809959) ; Int J Mol Sci. 2020 Jul 31;21(15):. (PMID: 32751841) ; Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541) ; Protein Pept Lett. 2017 Nov 17;24(9):784-792. (PMID: 28814250) ; Immunotherapy. 2020 Apr;12(5):269-273. (PMID: 32212881) ; JCO Glob Oncol. 2020 Apr;6:557-559. (PMID: 32250659) ; Pharmacol Ther. 2020 Aug;212:107555. (PMID: 32320730) ; Ann Oncol. 2020 Jul;31(7):838-839. (PMID: 32243894) ; Int J Oncol. 2021 Feb;58(2):145-157. (PMID: 33491759) ; Gastroenterology. 2020 Jun;158(8):2298-2301.e7. (PMID: 32234303) ; Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):505-518. (PMID: 31659104) ; Lancet Oncol. 2020 Apr;21(4):e180. (PMID: 32142622) ; Transl Res. 2020 Jun;220:1-13. (PMID: 32299776) ; Oncol Rep. 2013 Jun;29(6):2408-14. (PMID: 23545945) ; Oncol Rep. 2011 Nov;26(5):1157-64. (PMID: 21769437) ; Tohoku J Exp Med. 2009 Feb;217(2):123-31. (PMID: 19212105) ; Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) ; Methods Mol Biol. 2015;1282:1-23. (PMID: 25720466) ; Nature. 2020 Jul;583(7816):469-472. (PMID: 32408336) ; Front Physiol. 2017 May 08;8:276. (PMID: 28533754) ; Front Immunol. 2019 Oct 04;10:2186. (PMID: 31636628) ; Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859) ; Cancers (Basel). 2020 Aug 10;12(8):. (PMID: 32785162) ; Immunotherapy. 2020 Oct;12(15):1111-1114. (PMID: 32594820) ; Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. (PMID: 32352535) ; J Thorac Oncol. 2020 Jul;15(7):1137-1146. (PMID: 32360578) ; Neoplasma. 2020 Mar;67(2):402-409. (PMID: 31847529) ; Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) ; J Virol. 2010 Jan;84(2):1198-205. (PMID: 19864379) Grant Information: NPRP9-453-3-089 Qatar National Research Fund (QNRF); QUCG-CMED-18/19-2 Qatar University (QU); QUCG-CMED-20/21-1 Qatar University (QU) Substance Nomenclature: 0 (Biomarkers, Tumor) Entry Date(s): Date Created: 20210305 Date Completed: 20210312 Latest Revision: 20210312 Update Code: 20231215 PubMed Central ID: PMC7933131

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

COVID-19 engages clinical markers for the management of cancer and cancer-relevant regulators of cell proliferation, death, migration, and immune response.